Vumon (teniposide) / BMS - LARVOL DELTA

Teniposide plus cisplatin or carboplatin in recurrent high-grade glioma: Pre‑planned interim analysis of an ongoing multicenter, open‑label, single‑arm trial (ESMO 2026) - No abstract available

Clinical • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor

CircDNAH14-encoded Novel Protein Activates MTA1/EMT Axis via Antagonizing TRIM25 to Promote NSCLC Malignant Progression (IASLC-WCLC 2026) - "The in vitro and in vivo functional investigation established D-373 as an oncogenic protein driving NSCLC progression and cisplatin resistance. Additionally, by screening FDA-approved drugs in the ZINC15 database combined with BLI assays and functional verification, we found that teniposide directly targets D-373 to block the D-373-MTA1 interaction, thereby attenuating the MTA1/EMT signaling and NSCLC progression via accelerating TRIM25-mediated MTA1 degradation. Conclusions : Our findings identify D-373 as an oncogenic circRNA-encoded protein and elucidate its regulation on the MTA1/EMT axis, suggesting a promising and druggable target for precise therapy of NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Targeted Protein Degradation • MTA1

Podophyllotoxin Derivatives in Oncology: Mechanistic Insights, Therapeutic Applications, and Future Directions. (PubMed, Mini Rev Med Chem) - "Various derivatives of PTOX, including etoposide and teniposide, are well-established chemotherapeutics, although their use is largely hampered by systemic toxicity, low solubility, and drug resistance. Recent strategies involving the incorporation of PTOX into nanoparticles, hybrid molecules, and other bioactive systems have expanded its therapeutic potential by improving solubility, pharmacokinetics, and tumor selectivity. Overall, understanding structural modifications and molecular interactions of PTOX derivatives provides a strong foundation for the rational design of more potent and targeted anticancer agents."

Journal • Colorectal Cancer • Oncology • Solid Tumor • AMPK • CHEK2 • HIF1A • TWIST1

A Comparative Study on the Efficacy and Safety of Teniposide and Etoposide in the Primary Central Nervous System Germ Cell Tumors in Children (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University

New trial • CNS Tumor • Embryonal Tumor • Germ Cell Tumors • Oncology • Solid Tumor

Teniposide plus platinum for recurrent high-grade glioma: A pre-planned interim analysis of an ongoing multicenter, open‑label, single‑arm trial (SNO 2026) - No abstract available

Clinical • Brain Cancer • Glioma • High Grade Glioma • Solid Tumor

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (clinicaltrials.gov) - P2/3 | N=215 | Recruiting | Sponsor: Huashan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Teniposide facilitates macrophage phagocytosis by targeting the CD47-SIRPα axis and the candidate protein TRIM54 in lung cancer. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Further data suggested that Ten bound to TRIM54, which may be involved in CD47 ubiquitination and degradation. To summarize, our findings suggest that Ten down-regulates CD47 through its binding to both CD47 and TRIM54, thereby disrupting the CD47-SIRPα interaction, enhancing macrophage phagocytosis, cGAS-STING activation, and promoting M1 polarization, supporting the potential of targeting CD47 for lung cancer immunotherapy."

Journal • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • SIRPA • TRIM54

Enabling sustainable supply of the essential cancer medicines etoposide and teniposide in yeast. (PubMed, Science) - "By identifying key glycosyltransferases and executing more than 60 genetic edits involving 45 heterologous enzymes, the complex biosynthetic pathway of podophyllotoxin-type lignans was reconstructed in yeast. In this study, we established a chemoenzymatic route that streamlines the synthesis of etoposide and teniposide through a single chemical step from biosynthetic precursor 4'-demethyl-epipodophyllotoxin-4-O-glucoside, which enables a secure supply chain of these essential medicines."

Journal • Brain Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders. (PubMed, Bioorg Chem) - "Four compounds were prioritized for further investigation: binimetinib, olaparib, mizolastine, and teniposide. These results support the value of an integrated in silico/SPR pipeline for identifying SIRT3-binding scaffolds. However, the functional consequences of binding, isoform selectivity, and biological relevance in ATM-deficient disease models remain to be established."

FDA event • Journal • Ataxia • Immunology • Metabolic Disorders • Movement Disorders • Primary Immunodeficiency • Rare Diseases • ATM • SIRT3

Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report. (PubMed, Front Immunol) - "Subsequently, second-line salvage therapy, consisting of emapalumab in combination with teniposide and dexamethasone, was initiated to account for the CNS involvement. The patient achieved sustained, complete clinical response following use of this modified therapeutic approach. Our findings suggest that this combination regimen may offer a potentially feasible therapeutic alternative for managing patients with SLE-associated HLH accompanied by CNS involvement; however, given the single-case nature of this report, further validation in larger cohorts is needed."

Journal • Hemophagocytic lymphohistiocytosis • Immunology • Inflammatory Arthritis • Lupus • Pediatrics • Rare Diseases • Systemic Lupus Erythematosus

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CD19 CAR-T CELL THERAPY FOR CENTRAL NERVOUS SYSTEM LYMPHOMA: A CLINICAL EFFICACY AND SAFETY ANALYSIS (EHA 2026) - "All patients successfully received bridging therapy consisting of fotemustine, pemetrexed, orelabrutinib, and dexamethasone, followed by conditioning regimens, which were BEAM (fotemustine, etoposide, cytarabine, and melphalan) in 2 patients and fotemustine, thiotepa, and teniposide in 5 patients. Two patients developed infections, both of which were controllable. . Summary/Conclusion ASCT combined with CD19 CAR-T therapy demonstrates excellent efficacy and a favorable safety profile with newly diagnosed and relapsed/refractory CNSL, warranting further validation in larger cohorts with extended follow-up."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation

LONG-TERM OUTCOMES OF ALLO-HSCT FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NON-REMISSION OR MINIMAL RESIDUAL DISEASE POSITIVITY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (EHA 2026) - "Myeloablative conditioning regimens were administered, including total body irradiation (fractionated, total dose: 8–10 Gy) combined with etoposide (200 mg/m² for 3 days) or teniposide (100 mg/m² for 3 days), fludarabine (30 mg/m² for 5 days) or cladribine (5 mg/m² for 5 days), alternatively, cyclophosphamide (1.8 g/m² for 2 days) combined with rabbit anti-T-cell globulin. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine, mycophenolate mofetil, and short-course methotrexate...Per our institutional treatment protocol, transplant-related mortality was notably low; even in this heavily pretreated cohort of r/r B ‑ ALL, allo ‑ HSCT remains a safe and effective therapeutic option. In particular, among PH + patients, LFS can exceed 70%."

CAR T-Cell Therapy • Clinical • IO biomarker • Minimal residual disease • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia

Characterization of an Endophytic Fusarium odoratissimum Strain 25# from Dysosma versipellis with Putative Podophyllotoxin Production. (PubMed, Curr Microbiol) - "Podophyllotoxin has significant anti-tumour, anti-condyloma and anti-HIV characteristics, and its derivatives, such as etoposide (VP 16-213), teniposide (VM-26) and Etopophos, have been approved in the market by the US FDA and are widely used in the clinical treatment of various cancers, such as lymphoma, lung cancer and acute leukaemia. Furthermore, the mycelial ethyl acetate extract exhibited measurable cytotoxic activity against the HepG2 cell line (IC50 = 32.58 ± 1.61 µg·mL- 1). Quantitative correlation analysis suggested that the estimated PTOX-equivalent concentration in the crude extract was in reasonable agreement with the IC50 of the pure PTOX standard, indicating that F. odoratissimum 25# may represent a potential natural source of a compound putatively identified as podophyllotoxin."

Journal • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lung Cancer • Lymphoma • Oncology • Solid Tumor

pH-dependent mechanical stability of SARS-CoV-2 Mpro-inhibitor complexes revealed by steered molecular dynamics. (PubMed, J Biomol Struct Dyn) - "Here, we investigate the pH-dependent mechanical response of the SARS-CoV-2 main protease (Mpro) when bound to two herbal inhibitors (Gallocatechin gallate and Glabridin) and two synthetic compounds (Remdesivir and Teniposide) using steered molecular dynamics (SMD) simulations. Mechanistic analysis reveals that protonation of catalytic residues His41 and Glu166 reshapes hydrogen-bond networks and electrostatic interactions, explaining the ligand-specific responses. These findings demonstrate that environmental pH can invert inhibitor performance rankings, with rupture forces spanning ∼120-850 pN across ligands and exhibiting pronounced pH-dependent shifts, including a decrease for Gallocatechin gallate (∼800 to ∼600 pN) and a substantial increase for Glabridin (∼120 to ∼450 pN), highlighting the importance of incorporating mechanical metrics and pH variability into antiviral therapeutic development for physiologically variable microenvironments."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report. (PubMed, Front Oncol) - "Following surgical resection and postoperative concurrent chemoradiotherapy, the patient received adjuvant therapy combining teniposide (VM-26) and bevacizumab, which led to significant radiological and symptomatic improvement. By examining the efficacy of this individualized comprehensive strategy-integrating surgery, chemoradiotherapy, and targeted therapy with teniposide-we assess its potential mechanisms and clinical value. This case suggests a potentially effective treatment option for patients with H3K27M-mutant DMG."

Journal • Brain Cancer • CNS Tumor • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Combination therapy targeting genomic and signal transduction vulnerabilities in epithelioid hemangioendothelioma (AACR 2025) - "Because most EHE cells contain either the TAZ-CAMTA1 or YAP-TFE3 fusion proteins that activate a transcriptome that promotes several hallmarks of cancer, targeting the main way the fusions interact with DNA could mitigate these effects. Previous studies investigating the use of monotherapies to target cells expressing the fusion proteins show limited effectiveness. However, targeting both the interaction of the fusion proteins' ability to interact with DNA as well as an important pathway for EHE cells, such as the PI3K pathway, could lead to a greater effectiveness in decreasing EHE tumor progression."

Combination therapy • Liposarcoma • Oncology • Sarcoma • Solid Tumor • CAMTA1 • TAFAZZIN • TFE3

BEDB: a comprehensive binding energy database for molecular docking and dynamics: insights into Human Metapneumovirus (HMPV) Inhibitors. (PubMed, Database (Oxford)) - "MK-3207 and Etoposide exhibited docking scores of -10.3 and -9.6, respectively. Additional compounds, including Teniposide, UK432097, 85019940, Setileuton, Orvepitan, Cep-11981, Tadalafil, and VS-5584, were also analyzed, providing further insights into their binding mechanisms and potential therapeutic relevance. The database is developed using PHP, HTML, CSS, JavaScript, and Python and is freely accessible at https://www.pbed.habdsk.org/."

Journal

OTUD3-Mediated Deubiquitination Licenses TEX264 to Orchestrate ER-Phagy for KDM5B Degradation in Teniposide Lung Cancer Therapy. (PubMed, Eur J Pharmacol) - "To summarize, these findings demonstrate that Ten effectively inhibits lung cancer and activates immunocytes by KDM5B inhibition, which is regulated by TEX264-associated ER-phagy. Most importantly, OTUD3 serves as an essential target for enhancement of TEX264 stabilization."

Journal • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • KDM5B • TEX26 • TOP2A

Anti-Proliferative and Antioxidant Potential of Podophyllotoxin From the Endophytic Fungus Dactylonectria torresensis. (PubMed, Chem Biodivers) - "The study investigated Dactylonectria torresensis as a sustainable source of podophyllotoxin (PTOX), a key precursor for anticancer drugs such as etoposide and teniposide. PTOX production was optimized through a two-phase statistical approach: Plackett-Burman Design followed by Face-Centered Central Composite Design. Initially, D. torresensis produced 78.46 µg/g dry weight (DW) of PTOX, which increased 6.35-fold to 498.76 µg/g DW after optimization."

Journal • Breast Cancer • Oncology • Solid Tumor

Integrated biosynthesis of the lignan (-)-pluviatolide in resting and growing E. coli cells. (PubMed, Front Bioeng Biotechnol) - "A key intermediate in their biosynthesis in plants is (-)-pluviatolide, which directs the pathway towards various high-value lignans like (-)-podophyllotoxin - the precursor of the clinically relevant antitumor drugs etoposide and teniposide. The addition of glycerol and glucose as energy and carbon sources enhanced the productivity towards (-)-pluviatolide. LC-MS analysis revealed complete conversion of the substrate (+)-pinoresinol and the formation of (-)-pluviatolide with 99% product ratio in resting cells and 92% in growing cells."

Journal • Oncology

Teniposide + Bevacizumab: A Phase II Study on Efficacy and Safety in Recurrent Glioblastoma (ChiCTR) - P2 | N=33 | Not yet recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital

New P2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

STING activation by teniposide: a potential direct mechanism beyond cGAS stimulation. (PubMed, Front Immunol) - "These findings suggest that Teniposide activates STING through a previously unrecognized, cGAS-independent mechanism, while retaining potential for canonical cGAS-STING stimulation. Our combined computational and experimental evidence supports repurposing Teniposide as a STING agonist, highlighting new therapeutic possibilities for innate immune stimulation."

Journal • Hematological Malignancies • Immune Modulation • Immunology • Leukemia • Oncology • CGAS • IFI16 • IFNB1 • STING

Development and Validation of HPTLC Method for Estimation of Podophyllotoxin in Crude Extract, Isolated Podophyllotoxin and Marketed Mother Tincture of Podophyllum hexandrum Royle. (PubMed, Biomed Chromatogr) - "Podophyllotoxin, a naturally occurring cyclolignan isolated from the root and rhizomes of Podophyllum species is mainly used to synthesise etoposide and teniposide, which are used in various diseases. Similarly, the intraday precision ranged from 214.7 ± 19.55 to 443.6 ± 35.84, with a %RSD of 3.5-5.9. The chromatographic results suggest that the developed method can be used for the comparative identification of podophyllotoxin in the ethanolic extract, isolated podophyllotoxin and marketed mother tincture."

Journal

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy (ASH 2024) - "Therefore, this study increased the sample size, extended the follow-up time and set up a control group to analyze the efficacy and safety of fotemustine-containing regimens compared with HD-MTX-containing regimens in the treatment of newly diagnosed PCNSL patients.Methods : From April 2011 to December 2021, 114 patients with newly diagnosed PCNSL who received HD-MTX-containing regimens (HD-MTX plus cytarabine [HD-MA], rituximab, HD-MTX plus temozolomide [R-MT]) or fotemustine-containing regimens (fotemustine, teniposide plus dexamethasone [FTD], fotemustine, temozolomide plus dexamethasone [FVD], rituximab, fotemustine, pemetrexed plus dexamethasone [RFPD]) were retrospectively analyzed in this study...Neither the progression free survival (PFS) (P=0.783) nor the overall survival (OS) (P=0.918) exhibited remarkably difference between HD-MTX-containing group and fotemustine-containing group. Notably, we noted that patients treated with HD-MTX-containing regimens..."

Clinical • Anemia • Brain Cancer • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Melanoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Solid Tumor • Thrombocytopenia